(888) 552-6760 SCHEDULE AN APPOINTMENT

Fouad R. Kandeel,

Arthur D. Riggs Distinguished Chair in Diabetes & Metabolism Research; Professor and Chair, Department of Translational Research & Cellular Therapeutics

Biography photo
Location
Duarte Comprehensive Cancer Center
1500 East Duarte Road
Duarte, CA 91010
Specialties
Diabetes, Endocrinology and Metabolism
Education
Medical school:
Degrees
  • M.D., Ph.D., 1969, Faculty of Medicine and Kaser El Aini Hospital, Cairo University, Egypt, M.B., B.CH. (M.D.)

Fellowship
  • 1985-1986, Research Fellow in Nutrition and Metabolism, Harbor-UCLA Medical Center, Torrance, CA

  • 1984-1985, Clinical Fellow in Endocrinology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA

  • 1982-1984, Research Fellow in Endocrinology, Harbor-UCLA Medical Center, Torrance, CA

  • 1979-1981, Research Fellow in Endocrinology and Medicine, Central Birmingham Health District Hospitals, Birmingham, United Kingdom

Residency
  • 1975-1979, Central Birmingham Health District Hospitals, Birmingham, UK

Professional Experience
  • 2019-present, Arthur D. Riggs Distinguished Chair in Diabetes & Metabolism Research, City of Hope, Duarte, CA

  • 2020-present, Chair, Department of Translational Research & Cellular Therapeutics, Associate Director, Diabetes & Metabolism Research Institute at City of Hope, Duarte, CA

  • 2015-2020, Chair, Department of Diabetes, Endocrinology & Metabolism, City of Hope, Duarte, CA

  • 2011-2015, Director, Division of Development & Translational Diabetes and Endocrine Research, Beckman Research Institute of City of Hope, Duarte, CA

  • 2009-2015, Professor, Department of Diabetes and Metabolic Disease Research, Beckman Research Institute of City of Hope, Duarte, CA

  • 2008-present, Professor, Department of Diabetes, Endocrinology & Metabolism, City of Hope, Duarte, CA

  • 2008-2020, Chair, Department of Diabetes, Endocrinology & Metabolism, City of Hope, Duarte, CA

  • 1996-present, Associate Clinical Professor, Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA

  • 1999-2010, Assistant Program Director, General Clinical Research Center, City of Hope, Duarte, CA

  • 1999-2000, Acting Director, Department of Diabetes, Endocrinology & Metabolism, City of Hope, Duarte, CA

  • 1996-1998, Consultant Endocrinologist, King Faisal Hospital & Research Center, Riyadh, Saudi Arabia

  • 1991-1999, Assistant Staff Physician, Department of Diabetes, Endocrinology & Metabolism, City of Hope, Duarte, CA

  • 1982-1984, Assistant Program Director, General Clinical Research Center, Harbor-UCLA Medical Center, Torrance, CA

  • 1973-1975, Assistant Lecturer, Department of Biochemistry, Tanta University, Egypt

Academic Appointments
  • Professor and Chair, Department of Translational Research & Cellular Therapeutics
  • Director, Islet Cell Transplantation Program
  • Associate Director, Arthur Riggs Diabetes & Metabolism Research Institute
About Me

Fouad Kandeel, M.D., Ph.D., is the principal investigator on the islet transplantation trial to determine the safety and efficacy of islet cell transplantation as a treatment for patients with type 1 diabetes. In addition, Dr. Kandeel has recently concluded a clinical project to identify genes related to the development of type 2 diabetes and cardiovascular disease in the Hispanic population. He also continues to oversee the Diabetes and Cardiovascular Risk Reduction Program, which he established several years ago at City of Hope. Due to his strong background in endocrine tumors and thyroid cancer, Dr. Kandeel participates in the development of the national guidelines for the management of neuroendocrine tumors and thyroid cancer.

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.